Current pharmacotherapy of central precocious puberty by GnRH analogs: Certainties and uncertainties

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 12, 2013, Pages 1627-1639

  Bertelloni, Silvano ^a,b   Baroncelli, Giampiero I ^a,b  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

Adult height; Central precocious puberty; GnRH analogs; Goserelin; Histrelin; Leuprolide; Long term follow up; Reproductive function; Triptorelin

Indexed keywords

FOLLITROPIN; GOSERELIN; HISTRELIN; LEUPRORELIN; LUTEINIZING HORMONE; TESTOSTERONE; TRIPTORELIN;

BIOLOGICAL ACTIVITY; BODY COMPOSITION; BODY HEIGHT; BODY MASS; BONE AGE; BONE DENSITY; BONE MATURATION; CENTRAL PRECOCIOUS PUBERTY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOLLITROPIN BLOOD LEVEL; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GOLD STANDARD; HEADACHE; HOT FLUSH; HUMAN; HYDROPHOBICITY; LOCAL SKIN REACTION; LONG TERM CARE; LUTEINIZING HORMONE BLOOD LEVEL; META ANALYSIS; OBESITY; OSTEOPOROSIS; OUTCOME ASSESSMENT; OVARY POLYCYSTIC DISEASE; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL (TOPIC); PRECOCIOUS PUBERTY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR BINDING; RECOMMENDED DRUG DOSE; REPRODUCTION; REVIEW; SEXUAL MATURATION; SYSTEMATIC REVIEW; TESTOSTERONE BLOOD LEVEL; VAGINA BLEEDING;

GONADOTROPIN-RELEASING HORMONE; HUMANS; PUBERTY, PRECOCIOUS; UNCERTAINTY;

EID: 84880252825     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.806489     Document Type: Review

References (94)

1. Fuqua JS. Treatment and outcomes of precocious puberty: an update. J Clin Endocrinol Metab 2013;98:2198-207
2. Sørensen K, Mouritsen A, Aksglaede L, et al. Recent secular trends in pubertal timing: implications for evaluation and diagnosis of precocious puberty. Horm Res Paediatr 2012;77:137-45
3. Tena-Sempere M. Deciphering puberty: novel partners, novel mechanisms. Eur J Endocrinol 2012;167:733-47
4. Grumbach MM, Styne DM. Puberty: Ontogeny, neuroendocrinology, physiology, and disorders. In: Wilson JD, et al. editors. Williams textbook of endocrinology. 9th edition. W.B. Saunders, Philadelphia; 1998. p. 1509-625
5. Thamdrup E. Precocious sexual development, a clinical study of 100 children. Munksgaard, Kopenhagen; 1961. p. 104-5
6. Bridges NA, Christopher JA, Hindmarsh PC, et al. Sexual precocity: sex incidence and aetiology. Arch Dis Child 1994;70:116-18
7. Cisternino M, Arrigo T, Pasquino AM, et al. Etiology and age incidence of precocious puberty in girls: a multicentric study. J Pediatr Endocrinol Metab 2000;13(Suppl 1):695-701
8. De Sanctis V, Corrias A, Rizzo V, et al. Etiology of central precocious puberty in males: the results of the Italian Study Group for Physiopathology of Puberty. J Pediatr Endocrinol Metab 2000;13(Suppl 1):687-93
9. Chemaitilly W, Trivin C, Adan L, et al. Central precocious puberty: clinical and laboratory features. Clin Endocrinol (Oxf) 2001;54:289-94
10. Oerter-Klein K, Barnes KM, Jones JV, et al. Increased final height in precocious puberty after long-term treatment with LHRH agonists: the National Institutes of Health experience. J Clin Endocrinol Metab 2001;86:4711-16
11. Lee PA, Neely EK, Fuqua J, et al. Efficacy of leuprolide acetate 1-month depot for central precocious puberty (cpp): growth outcomes during a prospective, longitudinal study. Int J Pediatr Endocrinol 2011;2011:7
12. Carel JC, Eugster EA, Rogol A, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics 2009;123:e752-62
13. Partsch CJ, Sippell WG. Treatment of central precocious puberty. Best Pract Res Clin Endocrinol Metab 2002;16:165-89
14. Lahlou N, Carel JC, Chaussain JL, Roger M. Pharmacokinetics and pharmacodynamics of GnRH agonists: clinical implications in pediatrics. J Pediatr Endocrinol Metab 2000;13(Suppl 1):723-37
15. Boepple PA, Mansfield MJ, Wierman ME, et al. Use of a potent, long acting agonist of gonadotropin-releasing hormone in the treatment of precocious puberty. Endocr Rev 1986;7:24-33
16. Bouchot O, Soret SY, Jacqmin D, et al. Three-month sustained-release form of triptorelin in patients with advanced prostatic adenocarcinoma: results of an open pharmacodynamic and pharmacokinetic multicenter study. Horm Res 1998;50:89-93
17. Okada H, Doken Y, Ogawa Y, Toguchi H. Sustained suppression of the pituitary-gondadal axis by leuprorelin three-month depot microspheres in rats and dogs. Pharm Res 1994;11:1199-203
18. Dineen MK, Tierney DS, Kuzma P, et al. An evaluation of the pharmacokinetics and pharmacodynamics of the histrelin implant for the palliative treatment of prostate cancer. J Clin Pharmacol 2005;45:1245-9
19. Hirsch HJ, Gillis D, Strich D, et al. The histrelin implant: a novel treatment for central precocious puberty. Pediatrics 2005;116:e798-802
20. Lewis KA, Eugster EA. Experience with the once-yearly histrelin (GnRHa) subcutaneous implant in the treatment of central precocious puberty. Drug Des Dev Ther 2009;3:1-5
21. Rahhal S, Clarke WL, Kletter GB, et al. Results of a second year of therapy with the 12-month histrelin implant for the treatment of central precocious puberty. Int J Pediatr Endocrinol 2009;2009:812517
22. Bertelloni S, Mul D. Treatment of central precocious puberty by GnRH analogs: long-term outcome in men. Asian J Androl 2008;10:525-34
23. Paterson WF, McNeill E, Reid S, et al. Efficacy of Zoladex LA (goserelin) in the treatment of girls with central precocious or early puberty. Arch Dis Child 1998;79:323-7
24. Paterson WF, McNeill E, Young D, et al. Auxological outcome and time to menarche following long-acting goserelin therapy in girls with central precocious or early puberty. Clin Endocrinol (Oxf) 2004;61:626-34
25. Mul D, Oostdijk W, Otten BJ, et al. Final height after gonadotrophin releasing hormone agonist treatment for central precocious puberty: the Dutch experience. J Pediatr Endocrinol Metab 2000;13(Suppl 1):765-72
26. Heger S, Partsch CJ, Sippell WG. Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: final height, body proportions, body composition, bone mineral density, and reproductive function. J Clin Endocrinol Metab 1999;84:4583-90
27. Carel J-C, Roger M, Ispas S, et al. Final height after long-term treatment with Triptorelin slow release for central precocious puberty: importance of statural growth after interruption of treatment. J Clin Endocrinol Metab 1999;84:1973-8
28. Pasquino AM, Pucarelli I, Accardo F, et al. Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function. J Clin Endocrinol Metab 2008;93:190-5
29. Magiakou MA, Manousaki D, Papadaki M, et al. The efficacy and safety of gonadotropin-releasing hormone analog treatment in childhood and adolescence: a single center, long-term follow-up study. J Clin Endocrinol Metab 2010;95:109-17
30. Lazar L, Padoa A, Phillip M. Growth pattern and final height after cessation of gonadotropin-suppressive therapy in girls with central sexual precocity. J Clin Endocrinol Metab 2007;92:3483-9
31. Adan L, Chemaitilly W, Trivin C, et al. Factors predicting adult height in girls with central precocious puberty: implications for treatment. Clin Endocrinol 2002;56:297-302
32. Arrigo T, Cisternino M, Galluzzi F, et al. Analysis of the factors affecting auxological response to GnRH agonist treatment and final height outcome in girls with idiopathic central precocious puberty. Eur J Endocrinol 1999;141:140-4
33. Adan L, Chemaitilly W, Trivin C, et al. Factors predicting adult height in girls with idiopathic central precocious puberty: implications for treatment. Clin Endocrinol (Oxf) 2002;56:297-302
34. Chiocca E, Dati E, Baroncelli GI, et al. Body mass index and body composition in adolescents treated with gonadotropin-releasing hormone analogue triptorelin depot for central precocious puberty: data at near final height. Neuroendocrinology 2009;89:441-7
35. Mul D, Bertelloni S, Carel JC, et al. Effect of gonadotropin-releasing hormone agonist treatment in boys with central precocious puberty. Horm Res 2002;58:1-7
36. Carel JC, Lahlou N, Guazzarotti L, et al. Treatment of central precocious puberty with depot leuprorelin. French Leuprorelin Trial Group. Eur J Endocrinol 1995;132:699-704
37. Brito VN, Latronico AC, Cukier P, et al. Factors determining normal adult height in girls with gonadotropin-dependent precocious puberty treated with depot gonadotropin-releasing hormone analogs. J Clin Endocrinol Metab 2008;93:2662-9
38. Tanaka T, Niimi H, Matsuo N, et al. Results of long-term follow-up after treatment of central precocious puberty with leuprorelin acetate: evaluation of effectiveness of treatment and recovery of gonadal function. The TAP-144-SR Japanese Study Group on Central Precocious Puberty. J Clin Endocrinol Metab 2005;90:1371-6
39. Jaruratanasirikul S, Thaiwong M. Outcome of gonadotropin-releasing analog treatment for children with central precocious puberty: 15-year experience in southern Thailand. J Pediatr Endocr Met 2011;24:519-23; leuprolide
40. Cook JS, Doty KL, Conn PM, et al. Assessment of depot leuprolide acetate dose-adequacy for central precocious puberty. J Clin Endocrinol Metab 1992;74:1206-9
41. Partsch CJ, Hummelink R, Peter M, et al. Comparison of complete and incomplete suppression of pituitary-gonadal activity in girls with central precocious puberty: influence on growth and predicted final height. The German-Dutch Precocious Puberty Study Group. Horm Res 1993;39:111-17
42. Massart F, Federico G, Harrell JC, et al. Growth outcome during GnRH agonist treatments for slowly progressive central precocious puberty. Neuroendocrinology 2009;90:307-14
43. Lanes R, Soros A, Jakubowicz S. Accelerated versus slowly progressive forms of puberty in girls with precocious and early puberty. Gonadotropinsuppressive effect and final height obtained with two different analogs. J Pediatr Endocrinol Metab 2004;17:759-66
44. Schroeter M, Baus I, Sippell WG, et al. Long-term suppression of pituitary-gonadal function with three-month depot of leuprorelin acetate in a girl with central precocious puberty. Horm Res 2002;58:292-6
45. Carel JC, Blumberg JSeymour C, et al. Triptorelin 3-month CPP Study Group. Three-month sustained-release triptorelin (11.25 mg) in the treatment of central precocious puberty. Eur J Endocrinol 2006;154:119-24
46. Mart?nez-Aguayo A, Hernandez MI, Beas F, et al. Treatment of central precocious puberty with triptorelin 11.25 mg depot formulation. J Pediatr Endocrinol Metab 2006;19:963-70
47. Chiocca E, Dati E, Baroncelli GI, et al. Central precocious puberty: treatment with triptorelin 11.25 mg. ScientificWorldJournal 2012;2012:583751
48. Bertelloni S, Cassio A, Arrigo T, et al. Central precocious puberty: short term comparative data on treatment with monthly or long-acting three months depot triptorelin. J Pediatr Endocrinol Metab 2007;20(Suppl 2):297-305
49. Carel JC, Lahlou N, Jaramillo O, et al. Treatment of central precocious puberty by subcutaneous injections of leuprorelin 3-month depot (11.25 mg). J Clin Endocrinol Metab 2002;87:4111-16
50. Badaru A, Wilson DM, Bachrach LK, et al. Sequential comparisons of one-month and three-month depot leuprolide regimens in central precocious puberty. J Clin Endocrinol Metab 2006;91:1862-7
51. Mericq V, Lammoglia JJ, Unanue N, et al. Comparison of three doses of leuprolide acetate in the treatment of central precocious puberty: preliminary results. Clin Endocrinol 2009;71:686-90
52. Fuld K, Chi C, Neely EK. A randomized trial of 1-and 3-month depot leuprolide doses in the treatment of central precocious puberty. J Pediatr 2011;159:982-7
53. Lee PA, Klein K, Mauras N, et al. Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty. J Clin Endocrinol Metab 2012;97:1572-80
54. Isaac H, Patel L, Meyer S, et al. Efficacy of a monthly compared to 3-monthly depot GnRH analogue (goserelin) in the treatment of children with central precocious puberty. Horm Res 2007;68:157-63
55. Trueman JA, Tillmann V, Cusick CF, et al. Suppression of puberty with long-acting goserelin (Zoladex-LA): effect on gonadotrophin response to GnRH in the first treatment cycle. Clin Endocrinol (Oxf) 2002;57:223-30
56. Lewis KA, Eugster EA. Continual suppresion by the histrelin implant for the treatment of central precocious puberty when left in place for two years. Pediatric Academic Societies Meeting 2011;3285.1:abstract
57. Gillis D, Karavani G, Hirsch HJ, et al. Time to menarche and final height after histrelin implant treatment for central precocious puberty. J Pediatr 2013;doi:pii: S0022-3476(13)00045-0
58. Tonini G, Lazzerini M. Side effects of GnRH analogue treatment in childhood. J Pediatr Endocrinol Metab 2000;13(Suppl 1):795-803
59. Manasco PK, Pescovitz OH, Blizzard RM. Local reactions to depot leuprolide therapy for central precocious puberty. J Pediatr 1993;123:334-5
60. Johnson SR, Nolan RC, Grant MT, et al. Sterile abscess formation associated with depot leuprorelin acetate therapy for central precocious puberty. J Paediatr Child Health 2012;48:E136-9
61. Miller BS, Shukla AR. Sterile abscess formation in response to two separate branded long-acting gonadotropinreleasing hormone agonists. Clin Ther 2010;32:1749-51
62. Monroe BJ, Fallon SC, Brandt ML. Intraoperative sonographic localization of a fractured Supprelin implant in a pediatric patient: a case report. J Pediatr Endocrinol Metab 2012;25:167-9
63. Yeshaya A, Kauschansky A, Orvieto R, et al. Prolonged vaginal bleeding during central precocious puberty therapy with a long-acting gonadotropin-releasing hormone agonist. Acta Obstet Gynecol Scand 1998;77:327-9
64. Heger S, Muller M, Ranke M, et al. Long-term GnRH agonist treatment for female central precocious puberty does not impair reproductive function. Mol Cell Endocrinol 2006;254-255:217-20
65. Jay N, Mansfield MJ, Blizzard RM, et al. Ovulation and menstrual function of adolescent girls with central precocious puberty after therapy with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab 1992;75:890-4
66. Feuillan PP, Jones JV, Barnes K, et al. Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty. J Clin Endocrinol Metab 1999;84:44-9
67. Neely EK, Lee PA, Bloch CA, et al. Leuprolide acetate 1-month depot for central precocious puberty: hormonal suppression and recovery. Int J Pediatr Endocrinol 2010;2010:398639
68. Murram D, Dewhurst J, Grant DB. Precocious puberty: a follow up study. Arch Dis Child 1984;59:77-8
69. Feuillan PP, Jones JV, Barnes KM, et al. Boys with precocious puberty due to hypothalamic hamartoma: reproductive axis after discontinuation of gonadotropin-releasing hormone analog therapy. J Clin Endocrinol Metab 2000;85:4036-8
70. Bertelloni S, Baroncelli GI, Ferdeghini M, et al. Final height, gonadal function and bone mineral density of adolescent males with central precocious puberty after therapy with gonadotropin-releasing hormone analogues. Eur J Pediatr 2000;159:369-74
71. van der Sluis IM, Boot AM, Krenning EP, et al. Longitudinal follow-up of bone density and body composition in children with precocious or early puberty before, during and after cessation of GnRH agonist therapy. J Clin Endocrinol Metab 2002;87:506-12
72. Antoniazzi F, Bertoldo F, Zamboni G, et al. Bone mineral metabolism in girls with precocious puberty during gonadotrophin-releasing hormone agonist treatment. Eur J Endocrinol 1995;133:412-17
73. Tung YC, Lee JS, Tsai WY, et al. The effects of gonadotropin releasing hormone analogue therapy on girls with gonadotropin-dependent precocious puberty. J Formos Med Assoc 2007;106:826-31
74. Park HK, Lee HS, Ko JH, et al. The effect of gonadotrophin-releasing hormone agonist treatment over 3 years on bone mineral density and body composition in girls with central precocious puberty. Clin Endocrinol (Oxf) 2012;77:743-8
75. Chiumello G, Brambilla P, Guarneri MP, et al. Precocious puberty and body composition: effects of GnRH analog treatment. J Pediatr Endocrinol Metab 2000;13(Suppl 1):791-4
76. Traggiai C, Perucchin PP, Zerbini K, et al. Outcome after depot gonadotrophin-releasing hormone agonist treatment for central precocious puberty: effects on body mass index and final height. Eur J Endocrinol 2005;153:463-4
77. Aguiar AL, Couto-Silva AC, Vicente EJ, et al. Weight evolution in girls treated for idiopathic central precocious puberty with GnRH analogues. J Pediatr Endocrinol Metab 2006;19:1327-34
78. Palmert M R, Mansfield M J, Crowley W. Fet al. Is obesity an outcome of gonadotropin-releasing hormone agonist administraton? Analysis of growth and body composition in 110 patients with central precocious puberty. J Clin Endocrinol Metab 1999;84:4480-7
79. Arrigo T, De Luca F, Antoniazzi F, et al. Reduction of baseline body mass index under gonadotropin-suppressive therapy in girls with idiopathic precocious puberty. Eur J Endocrinol 2004;150:533-7
80. Leger J, Reynaud R, Czernichow P. Do all girls with apparent idiopathic precocious puberty require gonadotropin-releasing hormone agonist treatment? J Pediatr 2000;137:819-25
81. Palmert MR, Malin HV, Boepple PA. Unsustained or slowly progressive puberty in young girls: initial presentation and long-term follow-up of 20 untreated patients. J Clin Endocrinol Metab 1999;84:415-23
82. Lazar L, Pertzelan A, Weintrob N, et al. Sexual precocity in boys: accelerated versus slowly progressive puberty gonadotropin-suppressive therapy and final height. J Clin Endocrinol Metab 2001;86:4127-32
83. Oostdijk W, Rikken B, Schreuder S, et al. Final height in central precocious puberty after long term treatment with a slow release GnRH agonist. Arch Dis Child 1996;75:292-7
84. Saggese G, Pasquino AM, Bertelloni S, et al. Effect of combined treatment with gonadotropin releasing hormone analogue and growth hormone in patients with central precocious puberty who had subnormal growth velocity and impaired height prognosis. Acta Paediatr 1995;84:299-304
85. Lampit M, Golander A, Guttmann H, et al. Estrogen mini-dose replacement during GnRH agonist therapy in central precocious puberty: a pilot study. J Clin Endocrinol Metab 2002;87:687-90
86. Pucarelli I, Segni M, Ortore M, et al. Effects of combined gonadotropin-releasing hormone agonist and growth hormone therapy on adult height in precocious puberty: a further contribution. J Pediatr Endocrinol Metab 2003;16:1005-10
87. Michaud PA, Suris JC, Deppen A. Gender-related psychological and behavioural correlates of pubertal timing in a national sample of Swiss adolescents. Mol Cell Endocrinol 2006;254-255:172-8
88. Copeland W, Shanahan L, Miller S, et al. Outcomes of early pubertal timing in young women: a prospective population-based study. Am J Psychiatry 2010;167:1218-25
89. Johansson T, Ritzen EM. Very long-term follow-up of girls with early and late menarche. Endocr Dev 2005;8:126-36
90. Gluckman PD, Hanson MA. Evolution, development and timing of puberty. Trends Endocrinol Metab 2006;17:7-12
91. Mul D, Versluis-den Bieman HJ, Slijper FM, et al. Psychological assessments before and after treatment of early puberty in adopted children. Acta Paediatr 2001;90:965-71
92. Xhrouet-Heinrichs D, Lagrou K, Heinrichs C, et al. Longitudinal study of behavioral and affective patterns in girls with central precocious puberty during long-acting triptorelin therapy. Acta Paediatr 1997;86:808-15
93. Kim EY, Lee MI. Psychosocial aspects in girls with idiopathic precocious puberty. Psychiatry Invest 2012;9:25-8
94. Officio A, Griso G, Frascogna AR, et al. Adulthood issues in idiopathic central precocious puberty. J Pediatr Endocrinol Metab 2007;20(Suppl 2):325-9